Journal Article

Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study

Al Kuwari, Einas, Abdul Rahim, Hanan F., Mohamoud, Yasmin A., Ahmed, Ayeda A., Yassine, Hadi M., Kaleeckal, Anvar Hassan, Bertollini, Roberto, Ayoub, Houssein H., Latif, Ali Nizar, Chemaitelly, Hiam, Coyle, Peter, Al Kuwari, Mohamed Ghaith, Jeremijenko, Andrew, Al-Thani, Mohamed H., Tang, Patrick, Younuskunju, Shameem, Abu-Raddad, Laith J., Malek, Joel A., Butt, Adeel A., Al Kanaani, Zaina, Nasrallah, Gheyath K., Al Khal, Abdullatif, Al Romaihi, Hamad Eid, Shaik, Riyazuddin Mohammad

2021

Overview

The epidemiology of the SARS-CoV-2 B.1.1.7 (or Alpha) variant is insufficiently understood. This study's objective was to describe the introduction and expansion of this variant in Qatar and to estimate the efficacy of natural infection against reinfection with this variant. Reinfections with the B.1.1.7 variant and variants of unknown status were investigated in a national cohort of 158,608 individuals with prior PCR-confirmed infections and a national cohort of 42,848 antibody-positive individuals. Infections with B.1.1.7 and variants of unknown status were also investigated in a national comparator cohort of 132,701 antibody-negative individuals. B.1.1.7 was first identified in Qatar on 25 December 2020. Sudden, large B.1.1.7 epidemic expansion was observed starting on 18 January 2021, triggering the onset of epidemic's second wave, 7 months after the first wave. B.1.1.7 was about 60% more infectious than the original (wild-type) circulating variants. Among persons with a prior PCR-confirmed infection, the efficacy of natural infection against reinfection was estimated to be 97.5% (95% CI: 95.7% to 98.6%) for B.1.1.7 and 92.2% (95% CI: 90.6% to 93.5%) for variants of unknown status. Among antibody-positive persons, the efficacy of natural infection against reinfection was estimated to be 97.0% (95% CI: 92.5% to 98.7%) for B.1.1.7 and 94.2% (95% CI: 91.8% to 96.0%) for variants of unknown status. A main limitation of this study is assessment of reinfections based on documented PCR-confirmed reinfections, but other reinfections could have occurred and gone undocumented. In this study, we observed that introduction of B.1.1.7 into a naïve population can create a major epidemic wave, but natural immunity in those previously infected was strongly associated with limited incidence of reinfection by B.1.1.7 or other variants.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Adolescent / Adult / Aged / Aged, 80 and over / Antibodies / Basic Reproduction Number / Biology and life sciences / Causes of / Child / Cohort analysis / Coronaviruses / COVID-19 - epidemiology / COVID-19 - virology / COVID-19 vaccines / Disease transmission / Diseases / Epidemics / Epidemiology / Expatriates / Female / Genes / Genomes / Health surveillance / Humans / Immunity, Innate / Infections / Laboratories / Male / Medicine and health sciences / Middle Aged / Models, Theoretical / People and Places / Polymerase Chain Reaction / Population / Public health / Qatar / Qatar - epidemiology / Reinfection - epidemiology / Reinfection - virology / Relapse / Retrospective Studies / Risk factors / SARS-CoV-2 / Serology / Severe acute respiratory syndrome coronavirus 2 / Statistics / Surveillance / Time Factors / Young Adult